Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00968305 · ClinicalTrials.gov registry record
Interleukin (IL)-13 as a Marker in Pediatrics Asthma
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 19
- Enrollment target
NCT00968305: Completed study, sponsored by Rush University Medical Center.
NCT00968305 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00968305 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 19 participants
- Enrollment target
Study Summary
Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2008-11 |
| Est. Completion | 2009-08 |
What the finished NCT00968305 record still lists
NCT00968305 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00968305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00968305 about?
NCT00968305 is a clinical study titled "Interleukin (IL)-13 as a Marker in Pediatrics Asthma". Asthma is a very common childhood chronic illness and is generally more severe in African Americans. The investigators attempted to determine whether a specific immune marker is associated with lung function and asthma severity.
What is the current status of trial NCT00968305?
This trial is currently completed. The enrollment target is 19 participants. The study started on 2008-11. Estimated completion is 2009-08.
Who is sponsoring clinical trial NCT00968305?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia